ANGO 250117 7.50C (ANGO250117C7500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ANGO250117C7500

Watchlist

1.45
-0.12-7.64%

15min DelayClose Dec 24 13:00 ET

1.55High1.45Low

Intraday

5D
Daily

News

Press Release: AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
Dow JonesDec 19 17:01 ET
AngioDynamics, Inc. (NASDAQ:ANGO) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Simply Wall StDec 13 05:36 ET
AngioDynamics Analyst Ratings
BenzingaDec 10 12:28 ET · Ratings
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
Zacks Dec 10 10:35 ET
H.C. Wainwright Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsDec 10 07:31 ET · Ratings
Institutional Investors Have a Lot Riding on AngioDynamics, Inc. (NASDAQ:ANGO) With 74% Ownership
Simply Wall StDec 10 05:32 ET

Comments

Trytosaveabit

Dec 9 12:42

$AngioDynamics (ANGO.US)$ Not to shabby! Lets try to push for a NHOD? Hehehe

Trytosaveabit

Dec 9 05:04

News

$AngioDynamics (ANGO.US)$ The FDA Has Granted 510(k) Clearance For AngioDynamics' Nanoknife System For Prostate Tissue Ablation
Benzinga· 1 min ago

Jaguar8

Dec 9 05:01

NEWS

$AngioDynamics (ANGO.US)$
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation.
Th...

Trytosaveabit

Oct 23 07:15

Update

$AngioDynamics (ANGO.US)$ Benzinga· 1 min ago
AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System

Jaguar8

Sep 19 15:48

NEWS

$AngioDynamics (ANGO.US)$
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
AngioDynamics, Inc. (NASDAQ: ANGO) has launched the RECOVER-AV clinical trial to evaluate the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE) in the European market.
This multi-center, multi-national study follows the successful APEX-AV trial in the US, which showed significant impr...